KYTHERA Biopharmaceuticals (KYTH) Files $86.25M IPO
Tweet
Share
E-mailGet Alerts KYTH Hot Sheet
Join SI Premium – FREE
KYTHERA Biopharmaceuticals, Inc. (Nasdaq: KYTH) filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering amount its $86.25 million. KYTHERA plans to list on the Nasdaq under the ticker "KYTH."
The offering is being made through J.P. Morgan, Goldman, Sachs & Co., Leerink Swann, and Lazard Capital Markets.
KYTHERA Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market.
The offering is being made through J.P. Morgan, Goldman, Sachs & Co., Leerink Swann, and Lazard Capital Markets.
KYTHERA Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Columbus Circle Capital Corp. III closes $230M IPO on Nasdaq
- Apnimed files for initial public offering on Nasdaq
- Nuveen Churchill closes $100M note offering, totaling $400M due 2030
Create E-mail Alert Related Categories
IPOsRelated Entities
JPMorgan, LazardSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
